News | August 04, 2008

Lowering Cholesterol Early in Life Could Save Lives

August 5, 2008 - With heart disease maintaining top billing as the leading cause of death in the U.S., a team of University of California San Diego School of Medicine physician-researchers is proposing aggressive intervention to lower cholesterol levels as early as childhood is the best approach to reduce the incidence of coronary heart disease.

In a review article published in the Aug. 5, 2008 issue of the American Heart Association journal Circulation, pioneering lipid researcher Daniel Steinberg, M.D., Ph.D., professor emeritus of medicine at UC San Diego, and colleagues Christopher Glass, M.D., Ph.D. and Joseph Witztum, M.D., both UC San Diego professors of medicine, call current approaches to lowering cholesterol to prevent heart disease “too little, too late.”

They state that with a large body of evidence proving low cholesterol levels equate with low rates of heart disease, “our long-term goal should be to alter our lifestyle accordingly, beginning in infancy or early childhood” and that “instituting a low-saturated fat, low-cholesterol diet in infancy (seven months) is perfectly safe, without adverse effects…”

Steinberg said progress has been made in the treatment of coronary heart disease in adults with cholesterol lowering drugs like statins. However, while studies show a 30 percent decrease in death and disability from heart disease in patients treated with statins, 70 percent of patients have cardiac events while on statin therapy. Promising new therapies are under development, but with an alarming rate of coronary heart disease in the U.S. today, action to curtail the epidemic is needed today, he said

They propose lowering low-density lipoproteins (the so-called “bad cholesterol”) to less than 50 mg./dl., even in children and young adults as a safe and potentially life-saving standard through diet and exercise changes. Drug treatment may also be necessary in those at very high risk.

“Our review of the literature convinces us that more aggressive and earlier intervention will probably prevent considerably more than 30 percent of coronary heart disease,” Dr. Steinberg said. “Studies show that fatty streak lesions in the arteries that are a precursor to atherosclerosis and heart disease begin in childhood, and advanced lesions are not uncommon by age 30. Why not nip things in the bud?”

Physicians have been slow to measure cholesterol, much less prescribe cholesterol-lowering regimens in children and young adults who are otherwise healthy. However, the UC San Diego team notes that studies of Japanese men in the 1950s showed that consuming a low-fat diet from infancy resulted in lifelong low cholesterol levels, and their death rate from heart disease was only 10 percent of the rate of cardiac-related death in the U.S. Even with risk factors such as cigarette smoking and diabetes, heart disease deaths remained significantly lower in Japanese men with lifetime levels of low cholesterol. This protective effect was lost in Japanese who migrated to the U.S. and adopted a Western diet leading to higher blood cholesterol levels.

Interventions today typically begin in adults diagnosed with high cholesterol levels or other risk factors or symptoms of coronary artery disease. However, initiating cholesterol-lowering interventions in 50-year-old adults, even if successful, is unlikely to reverse established arterial disease and will therefore have limited impact on the occurrence of adverse events related to coronary heart disease.

Citing the success of lowering cholesterol levels in children diagnosed with familial hypercholesterolemia, the UC San Diego team suggests programs to lower cholesterol in the population at large from childhood on, with the ideal LDL level set at 50 mg./dl. or less (in those at highest risk) will have a long-term beneficial effect and lower the nationwide rates of coronary artery disease. They do not advocate using drug therapy to reach these levels, especially in children with no other risk factors, but to achieve these low levels through “TLC,” or “therapeutic lifestyle changes,” such as diet and exercise.

The National Institutes of Health (NIH) has declared “war” against the parallel epidemics of obesity and diabetes. The researchers conclude, “the weapons for those wars - education and behavior modification - are the same as those needed for a war on coronary heart disease.”

They propose a concerted national effort might dramatically reduce morbidity and mortality due to these three major chronic diseases. They admit it may take generations to achieve and it would require an all-out commitment of money and manpower to re-educate and modify the behavior of a nation. They wrote, “is that impossible? No. We have already shown that even a frankly addictive behavior like cigarette smoking can be overcome (eventually).”

For more information: www.ahajournals.org


Related Content

News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
News | Pharmaceuticals

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Home November 21, 2023
Home
Feature | Pharmaceuticals | By Christine Book

In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor ...

Home October 25, 2023
Home
Videos | Pharmaceuticals

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

Home September 26, 2023
Home
Videos | Pharmaceuticals

In Part 2 of DAIC’s 3-part “One on One” series with Dr. Christine Seidman, a discussion on the discovery of gene-based ...

Home September 11, 2023
Home
Videos | Pharmaceuticals

A 3-part video series with Christine E. Seidman, MD, FACC, FAHA In the first of this 3-part “One on One” series, Dr ...

Home August 28, 2023
Home
News | Pharmaceuticals

August 1, 2023 —LEXEO Therapeutics, a clinical-stage gene therapy company advancing adeno-associated virus (AAV)-based ...

Home August 01, 2023
Home
News | Pharmaceuticals

July 10, 2023 — Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio ...

Home July 10, 2023
Home
Subscribe Now